Kinfo
Nektar Therapeutics logo

Nektar Therapeutics

NKTRNASDAQHealthcare·US · USD
$37.27
+0.02 (+0.05%)
Prices as of November 13, 2026 · market closed

Price

Key statistics

Valuation
Market cap1.27B USD
Enterprise value788.13M USD
Trailing P/E-3.83
Forward P/E-3.61
PEG ratio0.07
Price / sales24.38
Price / book1.50
Profitability
Gross margin0.00%
Operating margin-303.57%
Profit margin100.00%
Return on assets-14.79%
Return on equity-37.92%
Income (TTM)
Revenue52.19M USD
Gross profit52.19M USD
EBITDA-157.76M USD
Net income-177.26M USD
Diluted EPS-$22.47
Rev. growth (YoY)-20.40%
Balance sheet
Total cash614.36M USD
Total debt128.67M USD
Debt / equity15.14
Current ratio9.00
Book value / share$24.86
Cash flow (TTM)
Operating cash flow-208.51M USD
Levered free cash flow-164.08M USD
Shares & price
Shares outstanding34.13M
Float28.31M
Held by institutions110.03%
Beta0.00
50-day MA$48.47
200-day MA$65.05
52-week high$109.00
52-week low$33.40
Dividends
Forward rate
$0.00
Yield
0.00%
Payout ratio
0.00%
Frequency
Monthly
Recent payments
  • 2014-06-11$0.00
Earnings (EPS)
DateEst.ActualSurprise2026-11-12-2.05-1.63+20.49%2026-08-13-2.04-1.21+40.69%2026-07-161.101.17+6.36%2026-05-07-1.48-1.78−20.27%2026-03-12-3.49-1.29+63.04%
About Nektar Therapeutics

Nektar Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing immunology and oncology medicines. Nektar Therapeutics’ current pipeline centers on therapies designed to address immune system dysfunction in autoimmune and chronic inflammatory diseases, with its lead candidate, rezpegaldesleukin, being evaluated in clinical programs for conditions such as atopic dermatitis, alopecia areata, and type 1 diabetes. The company also advances additional candidates across autoimmune, fibrotic, and cancer-related areas, including programs targeting ulcerative colitis, vitiligo, multiple sclerosis, and solid tumors. Through its proprietary chemistry and immunology expertise, Nektar Therapeutics develops highly selective therapeutic candidates intended to modulate key biological pathways and support precision treatment approaches across specialty disease areas.

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Howard W. Robin
Employees
63
Headquarters
San Francisco, CA, United States

Frequently asked questions about Nektar Therapeutics